Hormona is a London-based femtech startup founded in 2020 that builds digital tools and hardware to help women monitor, understand, and manage hormonal imbalances.[1][2][4] Its flagship product is a hormone tracking app allowing users to log menstrual cycles, symptoms, and well-being, with AI-driven insights into patterns; the company also offers at-home urine tests for estrogen, progesterone, and FSH (with over 90% accuracy vs. blood tests), supplements, and upcoming perimenopause tools, serving women in 185+ countries.[1][2][3][5] Targeting women facing hormone-related issues like those in menstrual cycles or perimenopause, Hormona solves the problem of inaccessible, trial-and-error healthcare by providing personalized, non-invasive tracking and expert-backed guidance, backed by a recent €7.8M ($6.7M) seed round for expansion.[1][2]
With 30% month-over-month app growth, 80% user retention after 12 months, and a team of 12 across London and Stockholm, Hormona demonstrates strong momentum in the women's health space.[1][2]
Hormona was co-founded in 2020 by Karolina Löfqvist (CEO) and Jasmine Tagesson (COO), childhood friends driven by Löfqvist's personal struggles with debilitating hormone-related symptoms that left her feeling unheard by traditional doctors.[1][2][4] Löfqvist's frustration with years of ineffective care inspired the creation of a platform empowering women with accessible tools, bridging gaps in women's healthcare.[4]
Early traction included app downloads in 190+ countries, awards like SLUSH100 (2021), TechCrunch Disrupt top 20 finalist (2022), Sweden’s Social Impact award, and Research Project of the Year by Femtech World.[3] The company raised seed funding led by Voima Ventures and Supernode Global VC, with participation from DLF Ventures, Nascent Invest, and Techstars, fueling hardware launches and international scaling.[1][2]
Hormona rides the femtech wave, capitalizing on rising demand for personalized women's health solutions amid growing awareness of hormonal issues overlooked by traditional systems.[1][4] Timing aligns with AI/healthtech convergence and at-home diagnostics post-COVID, enabling scalable, accurate tracking without clinical barriers—key as women's health funding surges despite market challenges.[2][3]
Market forces like aging populations (perimenopause focus) and digital health adoption favor Hormona, influencing the ecosystem by pioneering non-invasive tests and educating users, potentially setting standards for femtech accuracy and accessibility.[1][2][3]
Hormona is poised to launch its at-home device and perimenopause app, scaling globally with fresh capital for team growth, R&D, and validation—targeting real-time tracking ubiquity.[1][2] Trends like AI personalization, regulatory support for femtech, and supplement integration will propel it, evolving its influence from app leader to comprehensive hormone health platform. This positions Hormona to transform women's wellness, turning personal struggles into empowered, data-driven lives.
Hormona has raised $7.0M in total across 1 funding round.
Hormona's investors include Metaplanet, Rooks Nest Ventures, Voima Ventures.
Hormona has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Seed in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $7.0M Seed | Metaplanet, Rooks Nest Ventures, Voima Ventures |
